Objective To assess the efficacy of anti-tumour necrosis factor (TNF)-α agents in the treatment of refractory uveitic macular oedema (UME). Methods Patients with refractory UME treated with TNF-α blockers were retrospectively enrolled. Central macular thickness (CMT) was assessed at optical coherence tomography (OCT) at the start of TNF-α inhibition, after 3 and 12 months, and at the last follow-up visit. Results Thirty-six patients (56 eyes with UME) were enrolled. The mean follow-up period was 29.9±40.8 (4-184) months. A statistically significant decrease was observed in the frequency of UME (p<0.0001) and in the mean CMT values (p<0.0001) during the study period. Best corrected visual acuity improved in 35 eyes (62.5%), remained stable in 12 eyes (21.4%), reduced in 9 eyes (16.1%). The mean corticosteroid dosage significantly decreased during the study period (p=0.016). Conclusion TNF-α inhibitors represent a useful treatment in patients with severe or resistant UME.

Tosi, G. M., Vitale, A., Rigante, D., Sota, J., Emmi, G., Lopalco, G., Guerriero, S., Iannone, F., Vannozzi, L., Bitossi, A., Frediani, B., Cantarini, L., Fabiani, C., Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema, <<CLINICAL AND EXPERIMENTAL RHEUMATOLOGY>>, 2020; 38 (4): 621-625 [http://hdl.handle.net/10807/191874]

Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema

Rigante, Donato;
2020

Abstract

Objective To assess the efficacy of anti-tumour necrosis factor (TNF)-α agents in the treatment of refractory uveitic macular oedema (UME). Methods Patients with refractory UME treated with TNF-α blockers were retrospectively enrolled. Central macular thickness (CMT) was assessed at optical coherence tomography (OCT) at the start of TNF-α inhibition, after 3 and 12 months, and at the last follow-up visit. Results Thirty-six patients (56 eyes with UME) were enrolled. The mean follow-up period was 29.9±40.8 (4-184) months. A statistically significant decrease was observed in the frequency of UME (p<0.0001) and in the mean CMT values (p<0.0001) during the study period. Best corrected visual acuity improved in 35 eyes (62.5%), remained stable in 12 eyes (21.4%), reduced in 9 eyes (16.1%). The mean corticosteroid dosage significantly decreased during the study period (p=0.016). Conclusion TNF-α inhibitors represent a useful treatment in patients with severe or resistant UME.
2020
Inglese
Tosi, G. M., Vitale, A., Rigante, D., Sota, J., Emmi, G., Lopalco, G., Guerriero, S., Iannone, F., Vannozzi, L., Bitossi, A., Frediani, B., Cantarini, L., Fabiani, C., Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema, <<CLINICAL AND EXPERIMENTAL RHEUMATOLOGY>>, 2020; 38 (4): 621-625 [http://hdl.handle.net/10807/191874]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/191874
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact